Such a short follow-up makes the median number of DAOH a meaningless measure, a difference of 2 or 3 days DAOH before and after implantation being clinically irrelevant. In my opinion, DAOH should not be used, and especially not presented as a median, when the median reaches the end of follow-up. Post implantation DAOH was used before by Borioni et al. in a study on ICD and CRT-D implantations with a follow-up of minimum 3 years and maximum 8 years. The high median DAOH (97% for both devices) and the 5-year survival (free of cardiac transplant) obtained by the Kaplan-Meier method above 60% suggest that studies with even longer follow-up could beneficially use DAOH. Besides, Borioni et al. themselves advocate the calculation of DAOH "from administrative databases with full coverage of long follow-up periods". They also analysed the skewness of the DAOH distribution, recommending to run more research on patients located in the first quartile. Similarly if extending the follow-up of the present study is not feasible in terms of resources, I would suggest to furthermore describe the patients located on the left of the DAOH curve to identify those who would benefit from further clinical research (trends are already in the text: Maori population, patients with AF). Authors present DAOH as a composite outcome summarizing mortality, hospitalisations and morbidity. I obviously agree on the first two terms and on the fact that morbidity and admission rate are (partially) correlated, nevertheless resuming morbidity to a number of hospitalisations or hospital days seems simplistic, and contradictory to a claimed patient-centred outcome. Patient perspective, experience and quality of life are not captured by DAOH while severity is only partially captured by length of stay. Moreover, although the Introduction rightly presents quality of life as a paramount issue in heart failure patients, reduction in the number of admissions or length of stay cannot simply be translated as QoL improvement. Yet, as the number of (re)admissions and the time to death represent useful tools as factual, objective and practical measures available in administrative databases, I would suggest to reformulate some parts of the text and remove such statement as "DAOH is another new approach to measure QoL in HF patients" (page 18, line 10). There is no information on adverse events such as device-related complications: unsuccessful implantations, lead displacements, infections, coronary sinus dissection, inappropriate defibrillation, etc. Hence the discussion can only assume that differences in complication rates likely account for DAOH differences. Most of all there is no distinction between device-related hospitalisations, cardiovascular indication such as heart failure related hospitalisations and other causes hospitalisations. The principal diagnosis/reason of admission, readily available in the New Zealand NMDS, could have added such valuable information. On the other hand, I am not aware of the kind of information available on causes of death in the New Zealand databases but describing the 8 cases reported in the study would also have been highly beneficial (we only know that 6 of them had ICM and 2 NICM and that they all were implanted CRT-D). The conclusion states that "HF patients implanted with CRT have greater DAOH and % DAOH within 1-year follow-up". The question is greater than what? The comparator is unclear. The logical comparator would have been OPT (optimal pharmacological treatment), which would have require a control group and another study design. Some comparisons are done before and after implantation in one CRT group. In this case the period pre implant cannot be considered as OPT due to population heterogeneity (patients already implanted with pacemaker or ICD are included). Often CRT-D and CRT-P groups are compared to each other. As different indications and patient characteristics lead to a different choice in the device, I would suggest to present baseline and results by CRT group. Page 14. The fact that less women were admitted post implantation with fewer hospital days is not a relevant result as there were less women implanted. Comparing the reduction pre/post implant experienced by both groups versus each other would be more interesting than comparing post implant figures. In the gender cases though, this is implicit as the pre implant DAOH medians were similar (notwithstanding my objection to use such a parameter as discussed above). Page 15. The likelihood to have ICM and diabetes, the pre-implant number of admissions and cardiovascular history does not describe the influence of the type of device, on the contrary. They only reflect the differences in baseline characteristics. Like for gender, the DAOH reduction (before/after) should be compared between groups. All the more so since here the pre implant DAOH are different between CRT groups. The above remarks apply to the next two sections on aetology of heart failure and ethinicity. Similarly the dependent variable of the linear regression is the number of DAOH post implantation. The logical choice of dependent variable would have been the difference in DAOH measured before and after implantation. Otherwise it is assumed that the number of DAOH before implantation is completely captured by the independent variables. I doubt this assumption is plausible, especially when the outcome includes all-cause hospitalisations and all-cause mortality. Only two independent variables were found significantly associated with the post implant DAOH. Beyond the fact that the dependent variable seems inappropriate to me, it would be advisable to study interactions between variables. For instance some clinical variables are probably correlated with the type of CRT device implanted.
Minor comments
As a foreign reader, I would have been interested in a brief explanation on the persons who use health and disability support services in New Zealand (e.g. is it a universal coverage system?). In the Statistical Analysis section, please add that baseline characteristics were also summarised as mean and SD (age and QRS duration). It is remarkable that no severe HF (NYHA IV) patient was implanted with a CRT device during the 7-year study period. Is there an underlying reason other than pure random such as patient selection? Page 10 -line 44. Implant admissions are defined as contiguous admissions and rehabilitation period. Does it mean inter-hospitals transfers and in-hospital rehabilitation only? Number of deaths should be reported per characteristic in Table 2 . I understood they all occurred in CRT-D patients, but not how they are broken down by gender, ethnicity etc. Obviously the number of patients is insufficient to detect confounders explaining the higher adverse events and admissions in Maori population. Maybe it would also be worth mentioning that taking socio-economic factors into account in future studies, not only ethnicity, would allow to clarify the reasons of such differences. The manuscript contains some typos: on several pages, "length of hospital day" should be replaced by "length of hospital stay". The total percentages of stages of chronic kidney disease does not add up to 100% (Table 1) ; missing values, if applicable, should be reported. Table 2 shows 21 Maori participants whereas they were 10 in Table 1 .
REVIEWER
Gianluigi Savarese Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden REVIEW RETURNED 09-Oct-2018
GENERAL COMMENTS
The Authors performed a retrospective analysis of 177 HF who underwent CRT implantation between 2008 and 2014 in order to assess whether CRT reduced days alive and out of hospital (DAOH) and number of hospitalizations. After CRT implantation, a shorter length of hospital stay, an increase in DAOH and a reduction of the overall number of hospitalizations was observed. Notably, greater DAOH was also seen in those with non-ischemic cardiomyopathy.
The topic is relevant, the manuscript is well written, the statistical analyses are appropriate and the limitations well acknowledged.
REVIEWER

Jeff Bakal University of Alberta Canada
REVIEW RETURNED
10-Oct-2018
GENERAL COMMENTS
Suggest you include references for DAOH minor points for your IQRs give the numerical range. Suggest also including mean for DAOH (I realize it is highly skewed, the idea being to give a per patient estimate)
Also consider dropping the %DAOH outcome as it seems to be less descriptive. It is difficult to compare patients before and after CRT implant as most patients would be hospitalized with their index event leading causing heart failure in the year prior to the implantation.
VERSION 1 -AUTHOR RESPONSE
ANSWER: Thank you for this comment. Our cohort patients were more likely to be hospitalised with an episode of HF but not necessarily. We have acknowledged this in our Limitation section.
Reviewer: 2
Reviewer Name: Camberlin Although the aim of the authors to objectify the empiric benefit of CRT based on real-world data is highly commendable, the 1-year follow-up represents a major issue among the study limitations. Such a short follow-up makes the median number of DAOH a meaningless measure, a difference of 2 or 3 days DAOH before and after implantation being clinically irrelevant. In my opinion, DAOH should not be used, and especially not presented as a median, when the median reaches the end of follow-up. Post implantation DAOH was used before by Borioni et al. in a study on ICD and CRT-D implantations with a follow-up of minimum 3 years and maximum 8 years. The high median DAOH (97% for both devices) and the 5-year survival (free of cardiac transplant) obtained by the Kaplan-Meier method above 60% suggest that studies with even longer follow-up could beneficially use DAOH. Besides, Borioni et al. themselves advocate the calculation of DAOH "from administrative databases with full coverage of long follow-up periods". They also analysed the skewness of the DAOH distribution, recommending to run more research on patients located in the first quartile. Similarly if extending the follow-up of the present study is not feasible in terms of resources, I would suggest to furthermore describe the patients located on the left of the DAOH curve to identify those who would benefit from further clinical research (trends are already in the text: Maori population, patients with AF).
ANSWER: Thank you for your comments. Additional analyses, such as mean, interquartile range of DAOH are presented. Furthermore, the limitations of DAOH is further acknowledged in the Limitation section.
Authors present DAOH as a composite outcome summarizing mortality, hospitalisations and morbidity. I obviously agree on the first two terms and on the fact that morbidity and admission rate are (partially) correlated, nevertheless resuming morbidity to a number of hospitalisations or hospital days seems simplistic, and contradictory to a claimed patient-centred outcome. Patient perspective, experience and quality of life are not captured by DAOH while severity is only partially captured by length of stay. Moreover, although the Introduction rightly presents quality of life as a paramount issue in heart failure patients, reduction in the number of admissions or length of stay cannot simply be translated as QoL improvement. Yet, as the number of (re)admissions and the time to death represent useful tools as factual, objective and practical measures available in administrative databases, I would suggest to reformulate some parts of the text and remove such statement as "DAOH is another new approach to measure QoL in HF patients" (page 18, line 10).
ANSWER: Thank you for your suggestion This statement has been modified.
There is no information on adverse events such as device-related complications: unsuccessful implantations, lead displacements, infections, coronary sinus dissection, inappropriate defibrillation, etc. Hence the discussion can only assume that differences in complication rates likely account for DAOH differences. Most of all there is no distinction between device-related hospitalisations, cardiovascular indication such as heart failure related hospitalisations and other causes hospitalisations. The principal diagnosis/reason of admission, readily available in the New Zealand NMDS, could have added such valuable information. On the other hand, I am not aware of the kind of information available on causes of death in the New Zealand databases but describing the 8 cases reported in the study would also have been highly beneficial (we only know that 6 of them had ICM and 2 NICM and that they all were implanted CRT-D).
ANSWER: Thank you for your suggestion. The cause of deaths of the 8 cases have been added to the Result section. We have acknowledged in our Limitations section that our data do not provide specific information on the type of hospitalisation (HF-related vs non-HF-related) prior and post CRT implantation.
The conclusion states that "HF patients implanted with CRT have greater DAOH and % DAOH within 1-year follow-up". The question is greater than what? The comparator is unclear. The logical comparator would have been OPT (optimal pharmacological treatment), which would have require a control group and another study design. Some comparisons are done before and after implantation in one CRT group. In this case the period pre implant cannot be considered as OPT due to population heterogeneity (patients already implanted with pacemaker or ICD are included). Often CRT-D and CRT-P groups are compared to each other. As different indications and patient characteristics lead to a different choice in the device, I would suggest to present baseline and results by CRT group.
ANSWER: Thank you for your suggestion. A table of baseline characteristics of CRT-D vs. CRT-P patients has been added to the manuscript (Table 3) .
Page 14. The fact that less women were admitted post implantation with fewer hospital days is not a relevant result as there were less women implanted. Comparing the reduction pre/post implant experienced by both groups versus each other would be more interesting than comparing post implant figures. In the gender cases though, this is implicit as the pre implant DAOH medians were similar (notwithstanding my objection to use such a parameter as discussed above).
ANSWER: Thank you for your suggestion. A table of comparison pre/post implant DAOH between genders has been added (Table 5) in the Result section.
Page 15. The likelihood to have ICM and diabetes, the pre-implant number of admissions and cardiovascular history does not describe the influence of the type of device, on the contrary. They only reflect the differences in baseline characteristics. Like for gender, the DAOH reduction (before/after) should be compared between groups. All the more so since here the pre implant DAOH are different between CRT groups.
The above remarks apply to the next two sections on aetiology of heart failure and ethnicity.
ANSWER: Thank you for your suggestion. A comparison pre/post implant DAOH between CRT groups, aetiology of heart failure and ethnicity has been added (Table 5) in the Result section.
Similarly, the dependent variable of the linear regression is the number of DAOH post implantation. The logical choice of dependent variable would have been the difference in DAOH measured before and after implantation. Otherwise it is assumed that the number of DAOH before implantation is completely captured by the independent variables. I doubt this assumption is plausible, especially when the outcome includes all-cause hospitalisations and all-cause mortality.
Only two independent variables were found significantly associated with the post implant DAOH. Beyond the fact that the dependent variable seems inappropriate to me, it would be advisable to study interactions between variables. For instance, some clinical variables are probably correlated with the type of CRT device implanted.
ANSWER: Thank you for your suggestion. We have analysed the interactions of variables including clinical variables with type of CRT device implanted. The only significant interactions found were between two pairs of variables: 1) NYHA Class 1 and QRS Duration and 2) AF and ICM. A repeat model of multivariable linear regression has been performed (Table 6 ) and further explained in the Result and Discussion Sections.
Minor comments
As a foreign reader, I would have been interested in a brief explanation on the persons who use health and disability support services in New Zealand (e.g. is it a universal coverage system?).
ANSWER: Thank you for your suggestion. A brief description of New Zealand health system is added in the study design and population Section.
In the Statistical Analysis section, please add that baseline characteristics were also summarised as mean and SD (age and QRS duration).
ANSWER: Thank you for your suggestion. This has been added to the Statistical Analysis section.
It is remarkable that no severe HF (NYHA IV) patient was implanted with a CRT device during the 7-year study period. Is there an underlying reason other than pure random such as patient selection?
ANSWER: Affordability and capacity are of concern in the Northern Region of New Zealand. Considering current workforce, funding constraints and the conservative approach taken, the published 2010 New Zealand guidelines (Table 1) have more restrictive recommendations for CRT, therefore no NYHA class IV patients were included. This has been explained in Limitations Section.
Page 10 -line 44. Implant admissions are defined as contiguous admissions and rehabilitation period. Does it mean inter-hospitals transfers and in-hospital rehabilitation only?
ANSWER: Thank you for your comment. The implant admission was defined as all contiguous admissions pre-and post-implant date and included inter-hospital transfers and periods of rehabilitation after implant prior to first discharge home. This has been further explained in the Hospitalisations Section.
Number of deaths should be reported per characteristic in Table 2 . I understood they all occurred in CRT-D patients, but not how they are broken down by gender, ethnicity etc.
ANSWER: Thank you for your suggestion. These have been added in Table 2 .
Obviously the number of patients is insufficient to detect confounders explaining the higher adverse events and admissions in Maori population. Maybe it would also be worth mentioning that taking socio-economic factors into account in future studies, not only ethnicity, would allow to clarify the reasons of such differences.
ANSWER: Thank you for the suggestion. This has been added in the Discussion section.
The manuscript contains some typos: on several pages, "length of hospital day" should be replaced by "length of hospital stay".
ANSWER: These have been amended in the manuscript.
The total percentages of stages of chronic kidney disease does not add up to 100% (Table 1) ; missing values, if applicable, should be reported.
ANSWER: Thank you for this. The error has been corrected in Table 1 . Table 2 shows 21 Maori participants whereas they were 10 in Table 1. ANSWER: The error has been corrected in Table 2 .
Reviewer: 3
Reviewer Name: Gianluigi Savarese After CRT implantation, a shorter length of hospital stay, an increase in DAOH and a reduction of the overall number of hospitalizations was observed. Notably, greater DAOH was also seen in those with non-ischemic cardiomyopathy.
The topic is relevant, the manuscript is well written, the statistical analyses are appropriate and the limitations well acknowledged. ANSWER: Thank you for your suggestion. The numerical range for IQR has been added.
Suggest also including mean for DAOH (I realize it is highly skewed, the idea being to give a per patient estimate) ANSWER: Thank you for your suggestion. The mean for DAOH has been included.
Also consider dropping the %DAOH outcome as it seems to be less descriptive.
ANSWER: Thank you for your comment. The %DAOH has been omitted.
VERSION 2 -REVIEW
REVIEWER
Jeff Bakal Alberta Health Services, Canada REVIEW RETURNED 08-Nov-2018
GENERAL COMMENTS
The methods don't align with what was done (still includes the %DAOH and median only. The authors present both mean and Median DAOH and Mean. then the discussion relies on median as it was significant, but not a reason for one over the other. If they are presenting DAOH then the distributional components should be presented as well.
VERSION 2 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
Reviewer: 4
Reviewer Name: Jeff Bakal Institution and Country: Alberta Health Services, Canada
The methods don't align with what was done (still includes the %DAOH and median only. The authors present both mean and Median DAOH and Mean then the discussion relies on median as it was significant, but not a reason for one over the other. If they are presenting DAOH then the distributional components should be presented as well. 
GENERAL COMMENTS
The revisions have answered by concerns adequately.
